Effects and Mechanisms of Taurine as a Therapeutic Agent - PubMed (original) (raw)
Review
Effects and Mechanisms of Taurine as a Therapeutic Agent
Stephen Schaffer et al. Biomol Ther (Seoul). 2018.
Abstract
Taurine is an abundant, β-amino acid with diverse cytoprotective activity. In some species, taurine is an essential nutrient but in man it is considered a semi-essential nutrient, although cells lacking taurine show major pathology. These findings have spurred interest in the potential use of taurine as a therapeutic agent. The discovery that taurine is an effective therapy against congestive heart failure led to the study of taurine as a therapeutic agent against other disease conditions. Today, taurine has been approved for the treatment of congestive heart failure in Japan and shows promise in the treatment of several other diseases. The present review summarizes studies supporting a role of taurine in the treatment of diseases of muscle, the central nervous system, and the cardiovascular system. In addition, taurine is extremely effective in the treatment of the mitochondrial disease, mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), and offers a new approach for the treatment of metabolic diseases, such as diabetes, and inflammatory diseases, such as arthritis. The review also addresses the functions of taurine (regulation of antioxidation, energy metabolism, gene expression, ER stress, neuromodulation, quality control and calcium homeostasis) underlying these therapeutic actions.
Keywords: Antioxidation; Cytoprotection; ER stress; MELAS; Neurodegenerative diseases; Taurine.
Figures
Fig. 1.
Taurine-mediated protection against pathology and disease. High concentrations of taurine in most cells regulate physiological function of excitable tissues and mitochondria. Taurine protects CNS by decreasing ER stress and antagonizing neurotransmitter receptors of GABAA, glycine and NMDA. Protection of the cardiovascular system by taurine occurs through regulation of cell signaling, such as Ca2+ transport, ROS generation and protein phosphorylation. Supplementation of taurine ameliorates symptoms of MELAS and diabetes mellitus. The anti-inflammatory activity of taurine involves either the formation of taurochloramine in neutrophils or the attenuation of nitric oxide and prostaglandin E2 in inflammatory diseases, such as rheumatoid arthritis and osteoarthritis. Taurine depletion or taurine transporter KO leads to cardiac and skeletal muscle dysfunction. Taurine prevents sarcopenia in aged person by minimizing gradual muscle loss. CNS: central nervous system; FXS: fragile X syndrome; SSDD: succinic semialdehyde dehydrogenase deficiency; MELAS: mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes.
Fig. 2.
Comparison of MELAS and taurine deficiency in mitochondria. The mitochondrial disease, MELAS, is caused by specific point mutations in mitochondrial DNA (mtDNA) that codes for tRNALeu(UUR). Most of the point mutations of MELAS with 80% frequency occur at A3243G while mutations at T3271C exist with 10% frequency. In mtDNA, ND genes are shown in red color and tRNA genes are depicted as blue circles. The gene of tRNALeu(UUR) responsible for MELAS is located adjacent to ND1. The mutation in MELAS alters the structure of the tRNALeu(UUR) preventing the conjugation of taurine with the uridine base of the UAA anti-codon from forming 5-taurinomethyluridine (τm5U). MELAS patients also show reduced aminoacylation of taurine deficient tRNALeu(UUR) by leucine catalyzed by aminoacyl-tRNA synthetase (AS). Both reduced aminoacylation of tRNALeu(UUR) by leucine and formation of the taurine conjugate of τm5UAA-tRNALeu(UUR) prevent decoding of mitochondrial UUG-dependent proteins, including ND6, which is one of 44 protein subunits of complex I of the electron transport chain located in the mitochondria inner membrane. On the other hand, taurine deficiency has normal aminoacylation of tRNALeu(UUR) by leucine, but exhibits reduced formation of the taurine conjugate of τm5UAA-tRNALeu(UUR), which also prevents decoding of mitochondrial ND6 mRNA, resulting in increased superoxide generation and reduced ATP generation. MELAS: mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; ND6: NADH-ubiquinone oxidoreductase chain 6; mt IS: motochodrial intermembrane space; mtIM: mitochondrial inner membrane; LS: light strand; HS: heavy strand.
Similar articles
- Taurine ameliorates impaired the mitochondrial function and prevents stroke-like episodes in patients with MELAS.
Rikimaru M, Ohsawa Y, Wolf AM, Nishimaki K, Ichimiya H, Kamimura N, Nishimatsu S, Ohta S, Sunada Y. Rikimaru M, et al. Intern Med. 2012;51(24):3351-7. doi: 10.2169/internalmedicine.51.7529. Epub 2012 Dec 15. Intern Med. 2012. PMID: 23257519 - Dynamic derangement in amino acid profile during and after a stroke-like episode in adult-onset mitochondrial disease: a case report.
Fukuda M, Nagao Y. Fukuda M, et al. J Med Case Rep. 2019 Oct 21;13(1):313. doi: 10.1186/s13256-019-2255-9. J Med Case Rep. 2019. PMID: 31630688 Free PMC article. - Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial.
Ohsawa Y, Hagiwara H, Nishimatsu SI, Hirakawa A, Kamimura N, Ohtsubo H, Fukai Y, Murakami T, Koga Y, Goto YI, Ohta S, Sunada Y; KN01 Study Group. Ohsawa Y, et al. J Neurol Neurosurg Psychiatry. 2019 May;90(5):529-536. doi: 10.1136/jnnp-2018-317964. Epub 2018 Apr 17. J Neurol Neurosurg Psychiatry. 2019. PMID: 29666206 Free PMC article. Clinical Trial. - Review: taurine: a "very essential" amino acid.
Ripps H, Shen W. Ripps H, et al. Mol Vis. 2012;18:2673-86. Epub 2012 Nov 12. Mol Vis. 2012. PMID: 23170060 Free PMC article. Review. - Taurine and its analogs in neurological disorders: Focus on therapeutic potential and molecular mechanisms.
Jakaria M, Azam S, Haque ME, Jo SH, Uddin MS, Kim IS, Choi DK. Jakaria M, et al. Redox Biol. 2019 Jun;24:101223. doi: 10.1016/j.redox.2019.101223. Epub 2019 May 21. Redox Biol. 2019. PMID: 31141786 Free PMC article. Review.
Cited by
- The Comparative Analysis of Peptides in Enteral Nutrition Products and Foods for Special Medical Purposes.
Li H, Fang C, Hu Y, Xu J, Zhao W, Li L. Li H, et al. Foods. 2024 Aug 16;13(16):2557. doi: 10.3390/foods13162557. Foods. 2024. PMID: 39200483 Free PMC article. - Direct Molecular Action of Taurine on Hepatic Gene Expression Associated with the Amelioration of Hypercholesterolemia in Rats.
Song Q, Kobayashi S, Kataoka Y, Oda H. Song Q, et al. Antioxidants (Basel). 2024 Aug 14;13(8):990. doi: 10.3390/antiox13080990. Antioxidants (Basel). 2024. PMID: 39199235 Free PMC article. - Insights into the cardiovascular benefits of taurine: a systematic review and meta-analysis.
Tzang CC, Lin WC, Lin LH, Lin TY, Chang KV, Wu WT, Özçakar L. Tzang CC, et al. Nutr J. 2024 Aug 15;23(1):93. doi: 10.1186/s12937-024-00995-5. Nutr J. 2024. PMID: 39148075 Free PMC article. Review. - Oral Supplementation with Betaine Powder Ameliorated High Blood Pressure in Spontaneously Hypertensive Rats.
Pelpolage SW, Sasaki R, Shimada K, Nagura T, Uchino H, Han KH, Fukushima M. Pelpolage SW, et al. Metabolites. 2024 Jul 18;14(7):390. doi: 10.3390/metabo14070390. Metabolites. 2024. PMID: 39057713 Free PMC article. - Taurine modulates host cell responses to Helicobacter pylori VacA toxin.
Westland MD, Schrimpe-Rutledge AC, Codreanu SG, Sherrod SD, McLean JA, McClain MS, Cover TL. Westland MD, et al. Infect Immun. 2024 Aug 13;92(8):e0022424. doi: 10.1128/iai.00224-24. Epub 2024 Jul 8. Infect Immun. 2024. PMID: 38975764
References
- Airaksinen EM, Oja SS, Marnela K-M, Leino E, Paakkonen L. Effects of taurine treatment on epileptic patients. Prog Clin Biol. 1980;39:157–166. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources